The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis and Novo fine tuned its Wegovy cash-pay program.
Multinational companies in China’s vaccine market face headwinds amid an anti-corruption crackdown and rising competition.
Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...
GSK, led by boss Emma Walmsley (pictured), is using the data of 1.4m adults aged 65 and 66 to examine the impact of its ...
The study will analyse electronic health records of 65- and 66-year olds from the UK’s National Health Service (NHS).
UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...
Health and Me on MSN1d
UK Pharma Touts Shingles Vaccine To Prevent DementiaAt present, Shingrix is used to prevent herpes zoster (shingles), a painful skin rash caused by the varicella-zoster virus.
The British pharmaceutical giant is working with the U.K. Dementia Research Institute to exploit a “natural randomization” ...
The British drugmaker is using the health data of some 1.4 million people, some of whom received its Shingrix shot and some ...
Prominent outside scientists who help the NIH evaluate its internal research programs are being abruptly removed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback